Breaking
Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHDFDA Approves Guardant360 CDx Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast CancerRAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup
🇺🇸 FDA

R&D

Page 1 • 1 item

Gain critical insights into global pharmaceutical R&D trends, drug discovery pipelines, and clinical trial advancements. Drive your pharma strategy.

Moderna FDA Talks Focus on Phase 4 COVID Vaccine Data
NewsCOVID-19May 2, 2026

Moderna FDA Talks Focus on Phase 4 COVID Vaccine Data

Moderna is currently in discussions with the U.S. Food and Drug Administration (FDA) regarding the submission of Phase 4 data for its COVID-19 vaccine, mRNA-1273. These talks are crucial for understanding the vaccine's ongoing real-world effectiveness and post-marketing surveillance.

Dr. Hannah O'Connor